Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003
Ralf René Reinert,Susanne Reinert,Mark van der Linden,Murat Yücel Cil,Adnan Al-Lahham,Peter C. Appelbaum +5 more
TL;DR: The clonal profile, as analyzed by multilocus sequence typing (MLST), showed that the 18 fluoroquinolone-resistant strains were genetically heterogeneous, and seven of the 18 strains belonged to new sequence types not hitherto described in the MLST database.
Journal ArticleDOI
A multistate outbreak of Escherichia coli O157:H7 infections linked to alfalfa sprouts grown from contaminated seeds.
T Breuer,D H Benkel,Roger L. Shapiro,W. Hall,M M Winnett,M J Linn,J Neimann,Timothy J. Barrett,Stephen Dietrich,Frances P. Downes,D M Toney,J L Pearson,H Rolka,Laurence Slutsker,Paul M. Griffin,Investigation Team +15 more
TL;DR: New subtyping tools such as PFGE used in this investigation are essential to link isolated infections to a single outbreak.
Journal ArticleDOI
Molecular Basis of Azithromycin-Resistant Pseudomonas aeruginosa Biofilms
Richard J. Gillis,Kimberly G. White,Kyoung-Hee Choi,Victoria E. Wagner,Herbert P. Schweizer,Barbara H. Iglewski +5 more
TL;DR: In this article, the authors used DNA microarrays to identify differentially expressed transcripts in developing Pseudomonas aeruginosa biofilms exposed to 2 mug/ml AZM.
Journal ArticleDOI
Antimicrobial activity of essential oils and carvacrol, and synergy of carvacrol and erythromycin, against clinical, erythromycin-resistant Group A Streptococci
TL;DR: It is demonstrated that carvacrol acts either alone or in combination with erythromycin against eryTHromycin-resistant GAS and could potentially serve as a novel therapeutic tool.
Journal ArticleDOI
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.
Meredith Hackel,Masakatsu Tsuji,Yoshinori Yamano,Roger Echols,James A. Karlowsky,Daniel F. Sahm +5 more
TL;DR: It is concluded that cefiderocol demonstrated potent in vitro activity against a 2014–2016, worldwide collection of clinical isolates of carbapenem-nonsusceptible Enterobacteriaceae, MDR A. baumannii,MDR P. aeruginosa, S. maltophilia, and B. cepacia.